A Phase 1a/1b Study of SBP-101 in Previously Treated Subjects with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

A Phase 1a/1b Study of SBP-101 in Previously Treated Subjects with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs SBP 101 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Sun BioPharma
  • Most Recent Events

    • 10 Aug 2017 According to a Sun BioPharma media release, the company expects that the patients in the sixth cohort will complete their first cycle of dosing and observation by September 2017 and the Company expects to close this Phase 1a study by the end of September 2017.
    • 07 Jun 2017 According to a Sun BioPharma media release, dosing in the fifth cohort has been completed. After review of the fifth cohort patients by the Data Safety Monitoring Board (DSMB), it has been determined to dose the next cohort at a lower dose level in order to approach the Maximum Tolerated Dose (MTD) of SBP-101. Patients are currently being recruited for this next cohort and one patient has completed the first cycle of dosing, and this cohort of patients will be completed by August 2017.
    • 07 Jun 2017 Results from patients in the first 5 cohorts (n = 25) published in a Sun BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top